649 completed, 168 recruiting, 165 unknown, 155 terminated. 778 Phase 2, 344 Phase 3, 308 Phase 1, 41 Not applicable, 14 Phase 4.
Follow Leucovorin: new trials by email Literature Review of Leucovorin trials Research Report on Leucovorin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) - Colorectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 64 | 2026-10-20 | 2026-09-28 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil - Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Not yet recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 320 | 2026-10-01 | 2026-09-04 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-14 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Not applicable | Not yet recruiting | IMGT Co., Ltd. | 360 | 2026-09-01 | 2026-07-15 |
Showing 20 of 1353. Sign in to see all of them.
Colorectal Neoplasms (450) · Rectal Neoplasms (209) · Colonic Neoplasms (202) · Pancreatic Neoplasms (134) · Stomach Neoplasms (123) · Neoplasm Metastasis (98) · Neoplasms (66) · Esophageal Neoplasms (57) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (51) · Lymphoma (49) · Adenocarcinoma Of Esophagus (42) · Carcinoma, Hepatocellular (41) · Leukemia (41) · Burkitt Lymphoma (34) · Adenocarcinoma (32)
National Cancer Institute (NCI) (79) · Sun Yat-sen University (34) · Alliance for Clinical Trials in Oncology (30) · Memorial Sloan Kettering Cancer Center (30) · Children's Oncology Group (27) · M.D. Anderson Cancer Center (24) · Hoffmann-La Roche (21) · ImmunityBio, Inc. (20) · UNICANCER (20) · GERCOR - Multidisciplinary Oncology Cooperative Group (19) · European Organisation for Research and Treatment of Cancer - EORTC (17) · Fudan University (17) · National Institute of Allergy and Infectious Diseases (NIAID) (17) · Merck Sharp & Dohme LLC (16) · Pfizer (16)
United States (720) · China (201) · France (173) · Canada (151) · Germany (142) · Italy (134) · Spain (121) · United Kingdom (113) · Australia (109) · South Korea (98) · Japan (92) · Belgium (81) · Taiwan (78) · Puerto Rico (70) · Netherlands (46)
Feinberg J (5) · Jane Robertson (5) · Leonard B. Saltz, MD (5) · Marwan Fakih (5) · Ming Shi, MD (5) · Project Leader (5) · Alfredo Falcone, MD (4) · Bach Ardalan, MD (4)
PMID 36306483, PMID 31268130, PMID 21997132, PMID 33356421, PMID 37890117, PMID 39121442, PMID 32816630, PMID 35623069, PMID 40341124, PMID 12049862, PMID 12540794, PMID 21561347, PMID 23007406, PMID 23233662, PMID 23493136, PMID 26187751, PMID 26590194, PMID 26861604, PMID 27275632, PMID 27722750, PMID 27986363, PMID 28006055, PMID 29284596, PMID 29471013, PMID 30293873, PMID 30679026, PMID 30982686, PMID 31070690, PMID 31378656, PMID 31811950, PMID 32085892, PMID 32418078, PMID 32939319, PMID 33242441, PMID 33439695, PMID 33538338, PMID 33735476, PMID 34905388, PMID 36525610, PMID 36603187, PMID 36940261, PMID 37678921, PMID 38315963, PMID 38446568, PMID 40147791, PMID 40315406, PMID 40340830, PMID 40812353, PMID 41252656, PMID 41671463
U10CA098543 (19), U10CA031946 (17), U10CA180886 (16), 2017 (15), 2023 (15), 2016 (14), 2025 (14), U10CA032102 (14), 2015 (10), P30CA033572 (9), U10CA021115 (9), U10CA180820 (9), 2018 (8), U10CA180888 (8), 2009 (7)